Podcasts about biopsies

Dr. Zachary Bauer from Bronson Pulmonary Specialists explains the new procedures and invites the public to an opportunity to see the technology up close at a special event.See omnystudio.com/listener for privacy information.

How should prostate biopsy be performed in the MRI era, and what impact does biopsy strategy have on treatment planning?In this episode, Prof. Francesco Sanguedolce is joined by Prof. Francesco Giganti, Prof. Gianluca Giannarini and Prof. Lars Budäus to discuss the latest expert recommendations on prostate biopsy.The conversation explores the importance of high-quality MRI, targeted and perilesional biopsy strategies, the role of emerging imaging technologies and the ongoing debate surrounding systematic biopsy.The faculty also discuss how biopsy findings can influence decisions on focal therapy, nerve-sparing surgery and lymph node dissection, while highlighting current areas of consensus and the questions that still remain in clinical practice.ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy, European Urology, article in press. Doi.org/10.1016/j.eururo.2026.06.012)This podcast is brought to you in collaboration with the EAU Section of Urological Imaging.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Dr. Monty Pal and Dr. Roselle De Guzman discuss key abstracts from the 2026 ASCO Breakthrough Meeting, including the real-world impact of liquid biopsies for early multi-cancer detection, AI applications in colorectal cancer screening, and how global advances in breast, esophageal, and small cell lung cancers translate directly to diverse patient populations in the Asia-Pacific region. LINK TO FULL TRANSCRIPT

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

BUFFALO, NY – July 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on July 2, 2026, titled “Renal oncocytoma: Α case report and literature review.” The study was led by first and corresponding author Areti Kalfoutzou from the Second Propaedeutic Department of Internal Medicine, Attikon General Hospital, National and Kapodistrian University of Athens, Greece. Renal oncocytoma is a rare benign tumor of the kidney that accounts for approximately 5–9% of renal epithelial tumors. Although it is considered benign, it often resembles kidney cancer on imaging studies, making accurate diagnosis challenging. Because treatment strategies differ substantially between benign oncocytoma and malignant renal tumors, establishing the correct diagnosis is essential to avoid unnecessary surgery while ensuring appropriate patient care. In this report, the researchers describe the case of an 82-year-old woman who presented with two months of gross hematuria. Contrast-enhanced computed tomography (CT) identified a 55 × 34 mm exophytic lesion arising from the upper pole of the left kidney. Based on its imaging characteristics, the mass was initially classified as a Bosniak category IV renal lesion, raising strong suspicion for renal malignancy. Full press release - https://www.oncotarget.net/2026/07/06/rare-benign-kidney-tumor-case-highlights-value-of-biopsy-and-minimally-invasive-treatment/ DOI - https://doi.org/10.18632/oncotarget.28893 Correspondence to - Areti Kalfoutzou - areti.kalfoutzou@haf.gr Abstract video - https://www.youtube.com/watch?v=C7TBLT3tbfA Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28893 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cryoablation, image-guided biopsy, kidney neoplasms, minimally invasive surgery, renal oncocytoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Katie Krulisky and Dr. Marcus Pinto discuss the diagnosis and management of hereditary ATTR amyloidosis. Show citation:  Panrudkevich AH, Jones FJS, Shouman K, et al. Sensitivity of Nerve and Skin Biopsy and Fat Aspirate for Amyloid in Symptomatic Hereditary ATTR Amyloidosis With Peripheral Neuropathy. Neurology. 2026;106(11):e218033. doi:10.1212/WNL.0000000000218033 

Brandi manages the tennis pro shop at Willow Fork Country Club in Katy, the club behind Pretty in Pink, an annual golf and tennis fundraiser that raised $22,000 for The Rose in a single day. She had insurance, a routine mammogram, and no reason to expect a problem until her scan came back inconclusive, then abnormal, and a biopsy she was quoted at nearly $5,000 out of pocket. In this conversation, Brandi talks honestly about the fear of waiting, the relief of a benign result, and how her whole relationship with Pretty in Pink changed once she understood exactly how the fundraiser helps all women in need. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. How can a woman with insurance still face thousands of dollars in out-of-pocket costs for a breast biopsy? 2. What is Pretty in Pink and how does Willow Fork Country Club's annual event raise money for The Rose? 3. How does The Rose work with patients on payment plans when costs are still a barrier? 4. What does the biopsy experience at The Rose actually look like, from check-in to results? 5. Why do mammograms sometimes come back inconclusive or abnormal and require a follow-up biopsy? 6. How did community word-of-mouth, specifically a fellow club member, connect Brandi to The Rose? 7. What role does family history of breast cancer play in a woman's risk, and why do women often not know that history until they need it? 8. Why do women delay mammograms for years, and what finally motivates them to follow through? 9. How does fear of cost cause women, even insured women, to stop short of getting answers? 10. What makes The Rose's patient experience different from a hospital setting for breast biopsies? 11. How does surviving a cancer scare change the way someone engages with fundraising and advocacy? 12. What is the message Brandi carries to friends and colleagues who have never heard of The Rose? Timestamped Overview 00:00 Dorothy introduces the episode and Brandi's story: a routine mammogram, an abnormal result, a $5,000 biopsy quote, and how a club member pointed her to The Rose. 00:52 Dorothy describes how Brandi's story connects to Pretty in Pink and closes with the episode's call to action. 01:57 Dorothy welcomes Brandi and notes that her situation, insured but still facing barriers, is different from many Rose patients. 02:23 Brandi describes her mammogram journey: inconclusive first scan, abnormal second scan, then the call about the $5,000 biopsy cost. 02:48 Dorothy confirms the quote came through a hospital-based setting. 03:05 Brandi explains how club member Dina Russell, a breast cancer survivor, connected her to Shannon at The Rose. Her cost at The Rose came in under $1,000. 03:51 Dorothy asks how Brandi ended up managing a tennis pro shop. Brandi shares her background in auto dealership accounting and the career change when her husband's club had an opening. 04:39 Dorothy and Brandi discuss Willow Fork Country Club in Katy and the Pretty in Pink event, which raised $22,000 in a single day. 04:56 Brandi describes how the event works: silent auctions, raffle baskets, a 50-50 raffle, and a golf-and-tennis format open to members and guests. 06:01 Dorothy and Brandi confirm Pretty in Pink happens in one day, in October. 07:02 Dorothy asks who first suggested Brandi call The Rose. Brandi confirms it was Dina, a member who had personally been through breast cancer. 07:58 Dorothy asks how Brandi felt facing the biopsy cost. Brandi describes the fear and the support of her husband, family, and close friends. 09:50 Brandi describes arriving at The Rose, the nurses' warmth, and how she felt like a person rather than a number. 10:15 Dorothy and Brandi discuss the type of biopsy performed: ultrasound-guided, using the mammogram machine. 10:41 Brandi describes Dr. Trevino: he explained every step, asked if he could play music, put on Christian music, and even sang along to ease her nerves. 12:37 Brandi shares the outcome: the mass was benign, and Dr. Trevino noted it was so small that even if cancerous, treatment would have been minimal. 12:59 Dorothy and Brandi discuss the importance of staying consistent with mammograms, even after a benign biopsy. 14:05 Brandi reflects on how her relationship to Pretty in Pink changed once she understood what The Rose actually does for women. 14:38 Dorothy asks Brandi to address listener misconceptions about nonprofit care quality. Brandi says the facility, staff, and experience were outstanding from the front desk forward. 15:27 Brandi shares a moment in the waiting room where another patient told her, "God has you," which steadied her in a hard moment. 16:47 Brandi shares her family history: an aunt and a cousin, both out of state, had breast cancer. She didn't learn about her aunt until after her own scare. 18:11 Dorothy underscores the importance of asking family about cancer history and not being afraid to have those conversations. 19:34 Brandi admits she had delayed her mammogram by three years. Her doctor told her at a routine physical to get it done that day. She did. 20:04 Dorothy and Brandi discuss sharing the experience with friends. Brandi's close friend, whose mother died of breast cancer, had also navigated a biopsy. 23:32 Brandi highlights The Rose's payment plan option, which allowed her to put a deposit down and pay in installments, an option available to insured and uninsured patients. 26:14 Brandi shares what she was most afraid of losing: being present for her four grandchildren, ranging from eight months to seven years old. 27:23 Dorothy thanks Brandi. Brandi encourages listeners not to be scared to get their mammogram and to talk openly with family.See omnystudio.com/listener for privacy information.

In this episode of Intellectual Medicine, Dr. Stephen Petteruti challenges the conventional thinking around prostate biopsies, Gleason scores, and treatment decisions for prostate cancer. He explains why a high Gleason score, including Gleason 7, 8, or 9, may indicate a higher risk of progression but does not automatically prove that aggressive treatment will improve survival. Drawing on studies including the PROTECT-T trial, he argues that surgery, radiation, and watchful waiting often show similar long-term prostate cancer mortality outcomes, while invasive treatments can carry serious consequences. Dr. Petteruti also discusses why biopsy results may not always provide the clarity men are promised and why PSA, MRI, and PSMA testing can offer repeatable ways to monitor risk. Beyond the clinical discussion, he emphasizes the importance of vitality, peace of mind, and making informed decisions without being driven by fear. His core message is that men should preserve strength, independence, and quality of life while carefully weighing their options.Timestamps:(00:29) Why vitality matters before disease or decline(01:37) The false trade-off in prostate cancer treatment(02:30) What a Gleason score does and does not mean(04:13) Facing a Gleason 8 or 9 diagnosis without panic(04:36) Comparing treatment outcomes in high Gleason prostate cancer(06:27) What the PROTECT-T trial suggests about surgery, radiation, and monitoring(07:48) The difficult decision between treatment risk and regret(10:03) Why watchful waiting is not the same as taking action(12:29) Gleason scores, progression risk, and treatment outcomes(14:25) Why biopsy may not determine the best treatment path(15:35) PSA, MRI, and repeatable monitoring as alternatives(16:33) Why men with high Gleason scores still have time to think(17:27) Living with vitality while making prostate cancer decisions(18:37) Why prostate cancer care needs a broader health perspective(20:47) The mission behind Intellectual Medicine and the Men's Vitality GroupEnjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone, and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.

Dr. Katie Krulisky talks with Dr. Marcus Pinto about the diagnosis and management of hereditary ATTR amyloidosis.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org.  

Broadcast from KSQD, Santa Cruz on 6-25-2026: Dr. Dawn devotes the show's opening to ivermectin for COVID. She walks through critical thinking principles—considering the source, cross-verification, and recognizing self-interested claims—before reviewing the evidence. The most-cited 2021 Bulgarian study of 300 people showing 77% reduction lacked accessible methods, and larger trials capable of detecting even small benefits failed to confirm efficacy. On safety, the standard 12mg parasitic dose every few weeks is well-tolerated due to the blood-brain barrier and efflux pumps that keep ivermectin out of the brain, but daily long-term dosing has caused encephalopathy, liver and kidney damage, and birth defects. Critical drug interactions—macrolide antibiotics, verapamil, proton pump inhibitors, and beta blockers—disable the efflux mechanism, and high-fat meals increase absorption 2.5-fold. Dr. Dawn shares two inflammation formulas calculable from any CBC. The Systemic Inflammatory Index (neutrophils × platelets ÷ lymphocytes) flags runaway inflammation: 200-500 is good, above 900 warrants investigation and correlates with worse stroke outcomes and rising tumor burden. The SIRI (neutrophils x monocytes ÷ lymphocytes) detects chronic tissue inflammation and early innate immune activation: below 500 is good, above 1500 indicates trouble and correlates with cardiovascular mortality and arterial plaque from M1 macrophage activity. Dr. Dawn shares two takeaways from the Institute for Functional Medicine annual conference: in patients at high cardiovascular risk by cholesterol, each gram daily of combined EPA/DHA produces a 9% risk reduction, with bruising as the dose-limit signal. Additionally, a 15-minute walk within 30 minutes of a meal nearly eliminates postprandial inflammation. An emailer asks whether an endocrinologist's claim that vitamin D leaches calcium from bones is true. Dr. Dawn confirms that very high vitamin D (above 150 nanograms, with concern starting above 90) elevates 1,25-vitamin D, which stimulates osteoclast formation and increases C-telopeptide markers of bone breakdown. A crowdsourced question asks how histamines work in women. Dr. Dawn explains histamine functions as a CNS neurotransmitter promoting alertness, wakefulness, and pain perception (deficient in narcolepsy), and as a GI signal driving acid secretion, motility, and visceral sensation. Gut bacteria can convert histidine to histamine, and fish left to spoil can trigger anaphylactic-like reactions from accumulated bacterial histamine. She notes stomach acid treatments Tagamet and Zantac are H2 blockers rather than the more familiar H1 antihistamines, and confirms histamine correlates with hormones but not particularly with minerals. A crowdsourced question on B vitamins for women in their mid-twenties prompts Dr. Dawn to recommend prenatal vitamins for those who might become pregnant, and B100 complex with calcium taken with a little apple cider vinegar for those on restricted diets or eating mostly fast food. Another question asks about chest versus belly breathing. Dr. Dawn explains babies demonstrate proper diaphragmatic breathing (belly protrudes on inhalation) while accessory muscle use signals fight-or-flight—or pneumonia in a non-crying infant. Chest breathing raises adrenaline; belly breathing calms it in adults. How do I stop compulsive scratching? Dr. Dawn explains neurodermatitis has its own ICD-10 code alongside compulsive nail-biting and hair-pulling, and it is diagnosed by sparing of unreachable areas like the mid-back between shoulder blades. Treatment includes nail clipping, lubricants, covering scabbed areas, and Prozac—which uniquely among antidepressants has a secondary indication for neurodermatitis. Zurich researchers combined immature human nerve cells with magnetic nanoparticles to create 6-micrometer NPC bots that can be magnetically positioned at spinal cord injury sites and then triggered by pulsatile magnetic stimulation to mature into nerve tissue. Mice with severed spinal cords regained movement and brain-muscle electrical signals by day 34 after daily 30-minute treatments. A study of 15,000 people with myalgic encephalomyelitis/chronic fatigue syndrome identified eight genetic regions distinguishing them from controls. Two relate to immune response to infection—consistent with the post-infectious onset many sufferers describe, including roughly half of long COVID patients—and others link to the nervous system and chronic pain. Dr. Dawn frames ME-CFS as an immune system stuck in the "on" position, unable to brake against an enemy that is long gone. An emailer asks about prostate biopsy approaches. Dr. Dawn explains the new transperineal biopsy (through skin between scrotum and anus) reduces post-biopsy infection from 1.5% to near zero and eliminates prophylactic antibiotics, though it requires more anesthesia and time. Cancer detection rates match the transrectal approach when both use MRI targeting, and she expects the transperineal approach to become standard.

«Statt Gewebe zu entnehmen, reicht bei der sogenannten Liquid Biopsy eine einfache Blutentnahme», erklärt Heather Dawson vom Institut für Gewebemedizin und Pathologie der Universität Bern. Diese Flüssigbiopsie gilt als einer der spannendsten Ansätze der modernen Krebsmedizin. Doch wie gross ist ihr Potenzial und wo liegen die Grenzen? Gemeinsam mit Sabine Schmid vom Inselspital Bern ordnet Dawson den aktuellen Stand ein. Beide Expertinnen betonen, dass die Methode für viele Anwendungen noch nicht ausreichend erforscht ist und weiterhin kritisch untersucht werden muss. Im Zentrum der Folge steht Dawsons Forschung zu Darmkrebs: Flüssigbiopsien könnten künftig helfen, Therapien gezielter auf einzelne Patientinnen und Patienten abzustimmen, unnötige Untersuchungen und Behandlungen zu vermeiden und neue Wege für die Früherkennung zu eröffnen. Sicher ist: Liquid Biopsy wird noch einen grossen Einfluss auf die Krebsmedizin haben.

Lung cancer biopsies are still being done blind more often than you'd think, leading to costly diagnostic errors. In this episode, Reza Khorasaninejad, Founder & CEO at LEADOPTIK, discusses how advances in photonics and metasurface engineering are enabling highly miniaturized imaging systems for minimally invasive procedures. These innovations aim to address a major challenge in lung cancer biopsies: a lack of imaging guidance that can lead to significant diagnostic errors. Early clinical pilots across multiple sites are demonstrating strong performance, with one hospital already converting into a paying customer. Looking ahead, the company is partnering with Stanford Medicine to develop AI-driven decision support tools to further improve diagnostic accuracy. Tune in to learn how next-generation imaging and AI are changing that reality and helping physicians hit the right target the first time! Resources: Connect with and follow Reza Khorasaninejad on LinkedIn.Follow LEADOPTIK on LinkedIn and explore their website!

Season 3 of Prostate Talk continues with a deep dive into one of the most important topics in prostate cancer care: precision.In this second episode, Maude Pavageau welcomes Dr. Eduard Baco to discuss the critical role of accurate image fusion in prostate biopsy.From improving targeting accuracy to helping reduce missed diagnoses and supporting more personalized treatment decisions, this conversation highlights how technology is reshaping the prostate cancer journey.

Send us Fan MailA cancer diagnosis can change everything in an instant. One conversation. Three words: "You have cancer." Suddenly, patients and families are faced with uncertainty, fear, and countless questions about what comes next.In this episode of MedStar Health DocTalk, host Debra Schindler sits down with medical oncologist and hematologist Dr. Ankit Madan of MedStar Southern Maryland Hospital Center, to discuss the critical first steps after a cancer diagnosis. Dr. Madan explains how patients move from diagnosis to treatment, how cancer is staged, and why building a multidisciplinary care team is essential for the best possible outcomes.The conversation explores the emotional impact of hearing a cancer diagnosis, the importance of patient navigators, social workers, nutritionists, mental health professionals, and the role patients play as active partners in their own care. Dr. Madan also discusses treatment advances, clinical trials, immunotherapy breakthroughs, second opinions, and practical advice for patients and families navigating one of life's most challenging journeys.Whether you or a loved one has recently been diagnosed with cancer, this episode offers guidance, reassurance, and expert insight into what happens after the diagnosis—and how patients can move forward with confidence and support.Topics covered:• Coping with the emotional impact of a cancer diagnosis• Understanding cancer staging and treatment planning• The role of biopsies, CT scans, PET scans, and additional testing• Building a multidisciplinary cancer care team• Patient navigators, social workers, and support services• Shared decision-making and patient autonomy• When to seek a second opinion• Clinical trials and emerging cancer treatments• Immunotherapy and advances in cancer care• Nutrition, exercise, and mental health during treatment• Cancer survivorship and ongoing surveillanceTo learn more about cancer care at MedStar Health, visit MedStarHealth.org/Cancer.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In this powerful episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Rebecca Griffiths, who shares her extraordinary journey through kidney failure, dialysis, kidney transplantation and transplant loss.   Rebecca's story is one of resilience, determination and hope. After gaining approximately 25kg of fluid in a matter of days and requiring emergency treatment to drain fluid from around her heart, she found herself facing kidney failure without the support of a renal team. What followed was a life-changing journey that included dialysis, a kidney transplant, the devastating loss of that transplant and the challenge of starting again.   In this episode, Rebecca discusses:  

·      Podcast Host and Interviewee:  Host: Maya GrahamInterviewee: Santiago Cepeda Description  Dr. Maya Graham interviews Dr. Santiago Cepeda on his recent Neuro-oncology article entitled "Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial."

Join host Dr. Nikolaos Papadantonakis for an in-depth conversation with Dr. Sanam Loghavi of The University of Texas MD Anderson Cancer Center. In this episode, we take listeners inside the hematopathology lab to demystify what happens after a bone marrow biopsy is performed.Dr. Loghavi explains how traditional morphologic assessment is integrated with modern,  molecular testing to establish the diagnosis of myelodysplastic syndromes.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening.

Editor's Summary by Preeti Malani, MD, MSJ, and Tracy Lieu, MD, MPH, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from May 16-22, 2026.

May 22, 2026In this episode, Scott, Mark, and Dr. Ray Painter revisit ureteral stent removal and replacement coding after listener feedback highlighted the need for additional clarification on when cystoscopic codes versus fluoroscopic exchange codes apply. The discussion then shifts to emerging RAC audits targeting prostate artery embolization (PAE) claims involving CPT codes 37242 and 37243, emphasizing the importance of detailed documentation and medical necessity support. The episode wraps with a deep dive into Medicare's medically unlikely edit (MUE) for add-on code 55715 for additional prostate biopsy lesions—exploring why the edit conflicts with CPT guidance, how practices should report multiple lesions, and why appeals may be necessary to receive proper reimbursement. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Send us Fan MailCheck our the full viva in the Final Exam Coursehttps://anaesthesia.thinkific.com/courses/FinalExamFinal exam peper 2025.2 VIVA 4Viva StemYou are providing anaesthesia in the interventional radiology suite of your major hospital. On the list is a 22 year old woman who requires a CT-guided biopsy of a left renal mass that was discovered incidentally on abdominal imaging. The patient was admitted today for the procedure and is accompanied by her parents who are her legal guardians and carers. A postoperative bed has been booked for the patient.Medical HistorySevere cerebral palsy- spastic quadriplegia- moderate intellectual disabilityRecurrent aspiration pneumonia- severe gastro-oesophageal reflux- oropharyngeal dysphagia- gastrostomy feeding tube (feeds ceased for six hours)Anxiety- distress with medical proceduresEpilepsyMedications - Baclofen 10 mg tds - Levetiracetam 1000 mg bd- Pantoprazole 40 mg once dailyAllergies- Nil knownObservations- height 155 cm - estimated weight 40 kg estimated - (BMI approx. 16.6 kg/m2) - HR 90 bpm- BP 95/55 mmHg- SpO2 96% on room airPreoperative Investigations- Blood test results are normal- Blood Group and Hold has been conductedWhat are your specific considerations when planning anaesthesia care for this patient?---------Find us atInstagram: https://www.instagram.com/abcsofanaesthesia/Twitter: https://twitter.com/abcsofaWebsite: http://www.anaesthesiacollective.comPodcast: ABCs of AnaesthesiaPrimary Exam Podcast: Anaesthesia Coffee BreakFacebook Page: https://www.facebook.com/ABCsofAnaesthesiaFacebook Private Group: https://www.facebook.com/groups/2082807131964430---------Check out all of our online courses and zoom teaching sessions here!https://anaesthesia.thinkific.com/collectionshttps://www.anaesthesiacollective.com/courses/---------#Anesthesiology #Anesthesia #Anaesthetics #Anaesthetists #Residency #MedicalSchool #FOAMed #Nurse #Medical #Meded ---------Please support me at my patreonhttps://www.patreon.com/ABCsofA---------Any questions please email abcsofanaesthesia@gmail.com---------Disclaimer: The information contained in this video/audio/graphic is for medical practitioner education only. It is not and will not be relevant for the general public.Where applicable patients have given written informed consent to the use of their images in video/photography and aware that it will be published online and visible by medical practitioners and the general public.This contains general information about medical conditions and treatments. The information is not advice and should not be treated as such. The medical information is provided “as is” without any representations or warranties, express or implied. The presenter makes no representations or warranties in relation to the medical information on this video. You must not rely on the information as an alternative to assessing and managing your patient with your treating team and consultant. You should seek your own advice from your medical practitioner in relation to any of the topics discussed in this episode' Medical information can change rapidly, and the author/s make all reasonable attempts to provide accurate information at the time of filming. There is no guarantee that the information will be accurate at the time of viewingThe information provided is within the scope of a specialist anaesthetist (FANZCA) working in Australia.The information presented here does not represent the views of any hospital or ANZCA.These videos are solely for training and education of medical practitioners, and are not an advertisement. They were not sponsored and offer no discounts, gifts or other inducements. This disclaimer was created based on a Contractology template available at http://www.contractology.com.PerOral Endoscopic Myotomy Failed intubation | Final Exam Viva

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Cornelia Ding what to look for on the prostate cancer biopsy report. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41533]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Cornelia Ding what to look for on the prostate cancer biopsy report. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41533]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Cornelia Ding what to look for on the prostate cancer biopsy report. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41533]

Protect Your Retirement with a PHYSICAL Gold and/or Silver IRA https://www.sgtreportgold.com/ CALL( 877) 646-5347 - You Can Trust Noble Gold The baby boomers continue to worship Donald J Trump regardless of his actions, like the destruction of our economy with endless war and and no matter his betrayals. In fact, they still adore Erika Kirk and loathe Tucker, Candace and Thomas Massie because... Trump says they should. I also provide a bombshell regarding the US military and AI data centers, and a health upoate regarding the benefits of fasting. Then we discuss the issues with aluminum in deodorant and the best solution I have found with Elliot, the founder of Masculine Man. Thanks for tuning in. Masculine Man: The Best Aluminum Free Deodorant You Will Ever Use https://www.masculinemanessentials.com/SGTREPORT Use discount code is SGT for 10% off you order. Free shipping on orders over $75 DISCLAIMER: This video was conducted on behalf of Vault Strategic Mining Corp, and was funded by CAPITALIZ ON IT. I have been compensated for this video. I only express my opinion based on my experience. Your experience may be different. These videos are for educational and inspirational purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. There is no guarantee of gains or losses on investments. Please do your own due diligence. I am not a financial advisor, and this is not a financial advice channel. All information is provided strictly for educational purposes. It does not take into account anybody's specific circumstances or situation. If you are making investment or other financial management decisions and require advice, please consult a suitably qualified licensed professional. The securities of Vault Strategic Mining Corp are speculative, and the company has not yet achieved consistent positive cash flow from operations. As a growth-stage company, it anticipates negative cash flow for the foreseeable future as it focuses on development and commercialization efforts. Parties viewing this video should thoroughly review the company's public disclosure and documents available on sedarplus.ca. View the company's public disclosure and documents available on sedarplus.ca. See full disclaimer here: https://capitalizonit.com/vault/ https://rumble.com/embed/v77vamg/?pub=2peuz

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Matthew R. Cooperberg discusses when and how to biospsy for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41532]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Matthew R. Cooperberg discusses when and how to biospsy for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41532]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Matthew R. Cooperberg discusses when and how to biospsy for prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41532]

Send us Fan MailWhy are pathology vendors still speaking different image languages when radiology solved that problem decades ago?In this episode of DigiPath Digest #46, I talk through four papers that all point to a bigger issue in digital pathology: we are not only dealing with better algorithms. We are dealing with interoperability, workflow design, explainability, and whether the field is actually ready to use these tools well.I start with DICOM in digital pathology, because I think this is still one of the most important infrastructure questions in the field. Digital pathology has clear value for consultation, image analysis, archival, and workflow, but vendor-specific whole slide image formats still create silos. In the episode, I explain why DICOM matters, why adoption is still low, how the multi-resolution pyramid works, and why this is really about enterprise imaging and future-proofing, not just file conversion. Then I move into kidney transplant rejection, where the paper makes a strong case for multimodal precision diagnostics. Creatinine is late. Antibody testing can miss important biology. Biopsies can miss the area that matters. So the opportunity is not to replace pathology, but to combine biomarkers, biopsy, and machine learning in a way that is more useful than any one signal alone. I also talk about explainability here, because if a model gives a risk score, we need to know what contributed to it. The third paper focuses on perineural invasion in solid tumors, and I liked this one a lot because it shows how AI can help standardize something that is clinically important but still inconsistently detected and reported. Perineural invasion is not just a passive pathway of spread. The biology is more active than that, and the quantification can go far beyond a simple yes-or-no answer. This is a good example of where digital pathology can do something humans cannot realistically do by eye at scale. The last paper is on gastric cancer immunohistochemistry biomarkers and advanced quantification, including HER2, PD-L1, mismatch repair, and CLDN18.2. This section is really about complexity. We are now asking pathologists to visually score biology that is getting harder and harder to summarize consistently, especially when markers, spatial context, and multiplexing all start to matter at once. I make the case that computational pathology is becoming necessary here, not because pathologists are failing, but because the biology is outgrowing purely visual workflows. What ties these four papers together is simple: digital pathology is not only about remote reading anymore. It is about interoperability, quantification, explainable AI, and making pathology more precise in places where the old workflow is reaching its limit. If you are a pathologist, lab leader, or digital pathology trailblazer trying to figure out what actually matters right now, this episode will help you connect the dots.Episode Highlights 07:41 – Why DICOM still matters if we want digital pathology systems to work together. 14:39 – Current adoption of SVS, MRXS, and DICOM, and why DICOM is still lagging. 16:44 – How the DICOM whole slide image pyramid works and why it matters for workflow. 24:29 – Why kidney transplant rejection is still difficult to diagnose with any single marker. 29:18 – Why perineural invasion is clinically important and still inconsistently reported. 34:44 – How AI can quantify tumor-nerve relationships more consistently than visual review alone. 46:39 – Why gastric cancer biomarker scoring is getting too complex for purely visual workflows. 54:55 – Multiplexing, spatial biology, and why explainable AI matters in biomarker interpretation. 01:04:01 – What is really blocking digital pathology adoption: cost, workflow, regulation, or mindset? Resources mentionedDICOM / digital pathology interoperability paper https://pubmed.ncbi.nlm.nih.gov/42093730/Kidney transplant rejection, biomarkers, and artificial intelligence https://pubmed.ncbi.nlm.nih.gov/42073482/Perineural invasion in solid tumors with AI and machine learning applications https://pubmed.ncbi.nlm.nih.gov/42100436/Gastric cancer IHC biomarkers, advanced detection methods, and perspectives https://pubmed.ncbi.nlm.nih.gov/42075555/Digital Pathology Place https://digitalpathologyplace.comDigital Pathology 101 Free PDF book mentioned at the end of the episode through Digital Pathology Place.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send me a derm question or story through text or voicemail!In this episode, I dive into the diagnostic approach and long-term management of sterile nodular panniculitis in veterinary patients. We discuss everything from sampling claw folds and interpreting flaky cytology samples to biopsy techniques, infectious disease rule-outs, and when to consider JAK inhibitors as part of a treatment plan. If you've ever struggled with diagnosing challenging nodular cases or navigating long-term management decisions, this episode is packed with practical clinical insights you can apply in practice.Did you know you can submit a question or voicemail to the show by using the link at the top of the show notes? Send me any and all questions to be featured on an episode!Watch The Episode: https://www.youtube.com/@thedermvet3932Follow The Derm Vet Podcast: https://www.instagram.com/thedermvetpod/Follow Me: https://www.instagram.com/thedermvet/Timestamps00:00 Intro01:14 Itch Inquiry: Sampling Claw Folds and Flaky Samples06:00 Identifying Sterile Nodular Panniculitis08:54 Diagnostic Approaches and Biopsy Techniques09:56 Ruling Out Infectious Causes12:53 Use of JAK Inhibitors16:19 Long-term Management19:49 Outro

What if the most common diagnostic tool in men's health for the last 30 years was actually failing millions of patients?” For decades, the "blind" prostate biopsy was the gold standard a primitive 'hit or miss' approach that often missed aggressive tumors while over-treating harmless ones. But then came the PRECISION trial, a research earthquake that proved we've been doing it wrong.In this episode, we are joined by the architect of that revolution: Professor Veeru Kasivisvanathan. A Professor of Urology at University College London and a consultant at Cleveland Clinic London, Prof. Veeru is the elite surgeon-scientist who convinced a global medical community to stop stabbing in the dark. He led the landmark trials that made MRI the mandatory gatekeeper for prostate cancer, saving countless men from unnecessary invasive procedures. If you've ever wondered why your doctor is ordering an MRI before a needle, or why "contrast dye" might be a thing of the past, this conversation is your roadmap.In this episode, you'll learn:The Precision Paradigm: Why a third of men can safely avoid a biopsy altogether if their MRI is clear.The Prime Trial Breakthrough: Why high-quality "biparametric" scans mean you can likely skip the Gadolinium contrast without losing accuracy.The Focal Therapy Landscape: How "male lumpectomies" using HIFU and Cryotherapy are preserving potency and continence.The Future of "Robotic Nerve-Sparing": How pre-operative mapping is allowing surgeons to operate with a level of visibility once thought impossible.Timestamps:00:00 – Introduction: Is the "Blind" Biopsy Failing Men?01:30 – Meet Prof. Veeru Kasivisvanathan: The Surgeon-Scientist.04:15 – What Inspired the PRECISION Trial?08:45 – The Problem with the 30-Year "Standard of Care."12:20 – MRI as the Gatekeeper: Avoiding Unnecessary Biopsies.15:45 – The UK vs. US Healthcare Systems: Why Cost and Ethics Matter.21:00 – The PRIME Trial: Biparametric vs. Multiparametric MRI.28:30 – Is Gadolinium Contrast "Toxic"? Understanding the Risks.34:15 – MRI Quality Control: Why the Radiologist Matters More Than the Machine.40:30 – Genomic Biomarkers vs. Imaging: Do We Need Both?44:45 – Treatment Paradigms: Focal Therapy (HIFU/Cryo) explained.49:15 – When to Choose a Robotic Prostatectomy Over Focal Therapy.53:00 – How to Find Prof. Veeru and Closing Thoughts.Key Resources Mentioned:Prof. Veeru's Profile: University College London (UCL) & Cleveland Clinic London.The PRECISION Trial: Published in the New England Journal of Medicine.The BURST Research Collaborative: A global network of 30,000+ patients.___________________________________

Melissa Mariano is a 43-year-old Canadian flight attendant living in Dubai who was diagnosed with triple positive (ER+, PR+, HER2+) breast cancer after a routine mammogram...zero symptoms, zero lumps. She almost skipped her follow-up appointment. In this episode, she shares how she went from stage 0 DCIS to navigating Herceptin without chemo, low-dose "Baby Tam," the Dutch test, and a radical people-pleasing wake-up call that changed everything. In this episode we cover: How calcifications on a mammogram went from "nothing to worry about" to a biopsy — and why she delayed 4 months The vacuum-assisted biopsy that may have removed her invasive cancer entirely before surgery even happened Why her final pathology came back DCIS only, stage 0 — and what triple positive actually means 18 rounds of Herceptin (anti-HER2) with NO chemo — and the NCCN guideline that made that possible The Italian Clancy study on "Baby Tam" (5mg Tamoxifen) and why she's tapering down from 20mg Dutch test results: high estrogen, good methylation — what it means and what she's doing about it Supplements she's using: L-theanine, Relora, liposomal glutathione, DIM (cycled), NAC Sauna 2x/week, red light therapy, hyperbaric oxygen, yin yoga, sound healing, Reiki, breathwork — her full protocol Egg freezing for fertility preservation before starting Tamoxifen The people-pleasing pattern she believes contributed to her diagnosis — and the shift that changed everything Why she says: "I'm no longer a phony — but I am my priority" Links & Resources: Clancy Study on Low-Dose Tamoxifen (Baby Tam / 5mg): READ HERE NCCN Guidelines for Breast Cancer: READ HERE Connect with Melissa Mariano: https://www.instagram.com/melidubai/ Not Today Cancer Inner Circle (weekly live calls, community support): [INFO HERE] BrocElite: 20% off here Chapter Markers (estimated) 00:00 — Intro: Meet Melissa — Dubai life, flight attendant, Italian roots 04:00 — The mammogram that almost didn't happen: calcifications and a delayed follow-up 08:30 — Biopsy results: triple positive, Grade 2 IDC + high-grade DCIS 13:00 — MRI showed no mass enhancement — the biopsy may have removed the cancer 19:00 — Surgery, clear margins, final pathology: stage 0 DCIS 22:00 — 20 rounds radiation — spinning and yoga the whole way through 25:00 — Herceptin without chemo: the NCCN guideline that changed everything 28:00 — Tamoxifen side effects, Baby Tam, and the Italian Clancy study 34:00 — Dutch test results, functional gynecologist Dr. Maria, supplement protocol 38:00 — Sauna, red light, hyperbaric oxygen, yin yoga, sound healing 44:00 — "I'm no longer a phony — but I am my priority": the people-pleasing shift 50:00 — What cancer gave her: resilience, perspective, advocacy 54:00 — Closing: the "Nope. Not Today." shirt moment + not today cancer Medical disclaimer: This episode is for informational and educational purposes only and is not intended as medical advice. Always consult your own oncologist, physician, or qualified healthcare provider before making any decisions about your diagnosis, treatment, or supplement protocol.

Join Our 8 Week Root Cause Reset Masterclass Starts June 4 -->DianeKazer.com/RCR 50% Off Dr Judy Morgan's Books --> DrJudyMorgan.com Code: CHI50 10% Off Dr Judy Morgan's Supplements -->DrJudyMorgan.com Code DK10 Join Our Elite VIP Tribe --> DianeKazer.com/VIP Apply To Become A Patient --> DianeKazer.com/PATIENT If you've ever trusted your vet… followed the protocol… done "everything right" for your pet… …and still felt like something was off, then this episode is for you. I'm going live today on our CHI Podcast with holistic veterinarian, Dr. Judy Morgan and we are getting controversial… Not surface-level… not sugar-coated… but the conversations most pet owners aren't having (and honestly… most vets aren't either). Here's what we're diving into: ✨ Immuno-suppressants…what are they and why they leave your pet with virtually zero immune defense ✨ The truth about ticks… and those "tick boxes" mysteriously popping up all over the US ✨ Parasite protocols + Heartworm medications — the harm they actually do inside your furry friend's body ✨ The dangers of mRNA vaccines in pets ✨ Biopsies, c@nc$r and lipomas — when intervention may spread what you're trying to stop I'm not here to scare you. I'm here to aware you so you can embody your power as a pet owner. Because your dog or cat doesn't get to ask for a second opinion… you are their advocate. And when you innerstand what's really going on — you can make decisions from clarity, not pressure. If you've ever questioned: "Is this really the best option for my pet?" You'll want to hear this.

What if your prostate biopsy is missing the most important detail?In this powerful episode, Dr. Geo sits down with Dr. Jonathan Epstein, one of the most influential urologic pathologists in the world, to break down what's really happening behind your diagnosis.From Gleason scores to hidden aggressive patterns, this conversation reveals why pathology is the foundation of every prostate cancer decision — and why getting it right is critical.If you've had a biopsy, elevated PSA, or are considering treatment vs. surveillance… this episode is essential listening.⏱️ Timestamps00:00 – The Hidden Problem With Prostate BiopsiesWhy your diagnosis may not tell the full story02:00 – Meet Dr. Jonathan EpsteinA leader who helped define modern prostate cancer pathology04:30 – What Pathologists Actually Look ForUnderstanding normal vs. abnormal prostate tissue06:30 – Gleason Scores Explained SimplyWhat 3+3, 3+4, and 4+3 really mean09:00 – Why Gleason 6 Is So ControversialShould it even be called cancer?11:00 – The Real Risk Isn't Gleason 6What doctors worry about more13:00 – Active Surveillance: Who Is It For?Why more men are safely avoiding treatment14:30 – Pathology vs. BiologyHow research connects what we see to outcomes15:30 – The Most Important Details in Your ReportCribriform patterns, intraductal cancer, and why they matter17:00 – Understanding Gleason 7 (Grade Group 2 & 3)Low-risk vs. high-risk within the same score19:00 – When Cancer Becomes DangerousWhat defines aggressive disease21:00 – Gleason 9: Is It Already Spread?The truth about micro-metastasis23:00 – Why MRI and PSMA Scans Aren't PerfectWhat imaging can miss25:00 – Why Biopsies Still MatterEven in the era of advanced imaging26:00 – What Makes a “Good” BiopsyWhy technique matters more than you think29:00 – MRI-Guided vs. Random BiopsiesWhy both are still necessary30:00 – How to Read Your Pathology ReportWhat actually matters vs. what doesn't34:00 – Biopsy vs. Prostatectomy FindingsWhy results can change after surgery36:00 – How Often Pathology Is WrongWhy second opinions are critical38:00 – The Problem Patients Don't SeeYou don't know who's reading your biopsy41:00 – The Future: AI in PathologyWill machines replace doctors?45:00 – What Patients Should Do NextHow to advocate for yourself52:00 – Managing Anxiety Around PSA & BiopsiesA real conversation about fear56:00 – What to Do When You Get Your ResultsHow to approach your doctor and next steps01:03:00 – Final Advice: Take Control of Your Health

Strong outcomes often come from slowing down—not rushing into irreversible decisions.In this episode, Dr. Stephen Petteruti questions the automatic path from elevated PSA to biopsy, surgery, and radiation. He explains that biopsies can disseminate prostate cells, while the true impact on long-term metastatic risk remains uncertain. His approach favors sequential PSA monitoring, imaging, and disciplined observation over immediate intervention.Evidence does not clearly show that surgery or radiation extend life for many men, yet the side effects are well known which are sexual dysfunction, urinary issues, and metabolic decline. Supporting immunity, metabolic health, and overall resilience may matter more than acting quickly.Rethink your options and choose a path that protects both your health and your quality of life. Watch the full episode of Say NO to Prostate Cancer Biopsies, Surgery, and Radiation.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Learn more: https://www.drstephenpetteruti.com/ Learn more: https://www.intellectualmedicine.com/ Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠ Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠ Subscribe to Intellectual Medicine on:Apple Podcast: https://tinyurl.com/DrPetterutiApplePodcast Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast Disclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

This mini-series on Behind the Knife delves into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program and Cancer Surgery Standards Program. This episode highlights sentinel lymph node biopsy for breast cancer.Hosts:- Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology fellow at MD Anderson Cancer Center.- Lauren Postlewait, MD, FACS, is an Associate Professor of Surgery at Emory University School of Medicine and is the Medical Director of the Breast Center at Grady Memorial Hospital in Atlanta, GA.- Chantal Reyna, MD, FACS (@kprgrl3) is a Breast surgical oncologist at Loyola University Medical Center in Chicago, IL and serves as the oncology clinical lead for the breast service line.Guest:- Susan E. Pories, MD, FACS (@SusanPoriesMD) is a professor of surgery, vice chair for quality and safety, and director of the Rutger's Breast Center at the University hospital. Learning Objectives: -       Understand the definition and identification of axillary sentinel lymph node. -       Understand the technique for injecting tracer or dye to perform sentinel lymph node biopsy. -       Understand the importance of preincision drainage evaluation and transcutaneous localization.-       Understand techniques to minimize seroma formation.Links to Papers Referenced in this EpisodeOperative Standards for Cancer Surgery, Volume 1: Breast, Lung, Pancreas, Colonhttps://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/Kindle edition:https://www.amazon.com/Operative-Standards-Cancer-Surgery-Section-ebook/dp/B07MWSNFSBSentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial Lancet Oncol. 2010 Oct;11(10):927-33.https://pubmed.ncbi.nlm.nih.gov/20863759/Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection J Clin Oncol. 2016 Apr 1;34(10):1072-8.https://pubmed.ncbi.nlm.nih.gov/26811528/The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis World J Surg. 2012 Sep;36(9):2239-51. https://pubmed.ncbi.nlm.nih.gov/22569745/Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer Am J Surg. 2005 Oct;190(4):557-62.https://pubmed.ncbi.nlm.nih.gov/16164919/Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial JAMA Oncol. 2023 Nov 1;9(11):1557-1564.https://pubmed.ncbi.nlm.nih.gov/37733364/Choosing Wisely GuidelinesSociety of Surgical Oncology. Released 2016 July 12; last updated 2020 November 13. Choosing Wisely: Five Things Physicians and Patients Should Question.https://surgonc.org/wp-content/uploads/2020/11/SSO-5things-List_2020-Updates-11-2020.pdfPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewOral Board Simulator: https://app.behindtheknife.org/oral-board-simulatorTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Eve: God bless you for all you do. I had a routine mammogram in early 2025, followed by a bilateral breast ultrasound, they recommended 6 month monitoring due to multiple small cysts/masses (I have very dense breasts). I was advised to continue to monitor with ultrasounds every 6 months. At my March 2026 follow-up, they recommended a biopsy because one mass at the 9 o'clock position increased from 1 cm to 1.5 cm. For context, I had a benign biopsy in 2024 in the same breast (10 o'clock) and regret doing it out of fear. I feel that poking and probing can be more harmful. I'm worried about unnecessary procedures but don't want to ignore anything serious. Would short-term monitoring (repeat ultrasound in 3 months) be reasonable? The tech seemed inexperienced, could measurement error be possible?      Eve: Hi it's me again, I wrote in yesterday and after I spoke to my PCP about my hesitation on getting a breast biopsy, she was supportive and said why don't we do an MRI instead to be certain instead of poking and probing before knowing what it really is. The only thing is that it would have to be with contrast. What do you think? Less invasive, more real answers, but the contrast makes me anxious. Can I do a detox if I opt for the MRI vs the breast biopsy? Ty Doc.      Anonymous: Hi! Can you help provide advice on how to help with orange hands/elbows/feet? I've tested extremely high for beta carotene. I'm not sure why as I wasn't eating bushels of carrots, just trying to get a diversity of plants in each week but guess I steer towards vegetables with higher concentrations (squash, dark leafy greens, broccoli etc). I've practically eliminated all sources of it, but still seems not to improve much. Any advice would be helpful as it is embarrassing. Thanks!      Anonymous: Hi! What are your thoughts on using clean sources of nicotine treat things like long COVID, chronic fatigue, brain fog etc.. Thanks!      Nikita: Hi Dr Cabral, After 4 years of heavy hairloss, I finally corrected my iron-deficiency anemia (through prescription iron pills- only thing that worked). 6 months later my hairloss has finally slowed down a lot. However, I'm not noticing any type of regrowth. I'd love to get some of my density back after those 4 years of bad hairloss. I wanted to know your opinion on starting minoxidil for a temporary period of time just to wake up the hair follicles? I never took it before bc I don't want to commit to it forever, but do you think it could work for this case and then maybe I can stop it and the hair won't fall out again because now   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3733 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In today's episode, Dr. Paul Wheatley-Price chats with Dr. Natasha Leighl, Medical Oncologist and Lung Site Lead at the Princess Margaret Cancer Center in Toronto, all about liquid biopsies. What is a biopsy, the difference between a tissue vs liquid biopsy, how does it work, when it can be done, and where is it available in Canada? Dr. Leighl gets into all the details with her renowned expertise in this topic!

Send me a derm question or story!In this week's episode, we explore an interesting feline case that illustrates why no detail should ever be overlooked. When a "perky nose" complaint actually becomes plasma cell pododermatitis.Using this case as a guide, we highlight how critical it is to go beyond the presenting complaint. A thorough dermatologic exam, combined with a detailed history, can uncover subtle abnormalities that completely change your diagnostic path, treatment plan, and ultimately, patient outcome. It's a good reminder that even when a diagnosis seems obvious, there could be clinical clues that point you a different direction.We discuss how this case unfolded, what could have been missed with a more limited approach, and practical strategies to ensure you're consistently gathering complete information in every appointment.References:Declercq J, DeBosschere H. Nasal swelling due to plasma cell infiltrate in a cat without plasma cell pododermatitis. Vet Dermatol. 2010;21:412–414. doi: 10.1111/j.1365-3164.2010.00869.x.Brosseau G. Feline plasma cell pododermatitis. Can Vet J. 2022 May;63(5):545-548. PMID: 35502252; PMCID: PMC9009751.Timestamps00:00 Intro03:50 The Swollen Nose07:02 Deflated Paws09:12 Biopsy and Diagnosis Confirmation12:09 Importance of Looking at the Complete History16:53 Outro

“It's ultra stable. Health care doesn't move. If you biopsied American health care in 2010 and again in 2026, no one could figure out which slide was which.” — Robert Pearl, MDBad news. The patient, I'm afraid, is ultra-stable. Robert Pearl, former CEO of Kaiser Permanente for eighteen years and author of ChatGPT MD, returns with the bleakest diagnosis we've heard all month. American healthcare, Dr Pearl says, is “ultra stable.” That might sound good. But it's actually very very bad.If you biopsied American healthcare in 2010 and again in 2026, Pearl says, no clinician could tell the slides apart. Both were and are overpriced. Both underperforming. Hospitals still represent between 30-35% of expenses. Costs continue to rise at between 7-9% a year. There remain four hundred thousand misdiagnosis deaths annually. Burnout is stuck at 50%. The numbers haven't moved in fifteen years.Meanwhile, a stealth revolution is already underway. 40% of Americans use generative AI every month for medical questions. 70-80% of physicians use it weekly. While the patients and doctors have moved, the system hasn't. It remains ultra-stable. It's a Kodak moment — healthcare's business model, Pearl suggests, is selling sickness. So, for example, the new new medical thing is GLP-1 drugs that cost $5 to manufacture and sell for $400.So will the system collapse? No, Pearl insists. It has too much strength for that kind of drama. Instead, it will quietly ration us to death — more chronic disease, earlier deaths, more people making a major sacrifice to pay their healthcare bills. Ultra-stability, then, is what is killing the American healthcare system. It will, quite literally, ration us to death. Five Takeaways•       Ultra Stable: Pearl's diagnosis of American healthcare in one phrase. Hospitals stay at thirty to thirty-five per cent of total expenses. Costs rise at seven to nine per cent annually. Life expectancy hasn't budged. Four hundred thousand misdiagnosis deaths a year. Burnout at fifty per cent. Biopsy 2010 and 2026 — no one could tell the slides apart. Both overpriced. Both underperforming.•       The Stealth Revolution Has Already Happened: Forty per cent of Americans use generative AI every month for medical questions. Seventy to eighty per cent of physicians use it weekly. The patients and doctors have moved. The system hasn't. It's a Kodak moment — they had the first filmless camera and let it die because their business model was selling film. Healthcare's business model is selling sickness.•       Quietly Rationed to Death: There will be no dramatic collapse. The system has too much strength for that. Instead: rationing, more chronic disease, earlier deaths. Like airlines moving everyone into first class while the rest drive. Twenty-five per cent of Americans already made a major sacrifice to pay healthcare bills last year. When it hits fifty per cent, maybe the polling places will notice. Pearl is doubtful.•       GLP-1s Cost $5 to Make and $400 to Buy: Yale's analysis: the manufacturing cost of a GLP-1 drug is $5 a month. They sell at a discounted price of $400. That's eighty times markup. Pearl's math: to make GLP-1s cost-neutral against the medical savings, the price has to be under $200. Trump Rx won't help most people because you can't use insurance there and $400 cash is still impossible on $60,000 a year.•       Vibe Coding Is the Prescription: One year old. Lets clinicians build software in plain English without code. Pearl's example: a heart failure patient at home, weighed daily on a Bluetooth scale, with an electronic stethoscope, ankle video, blood oxygen, exercise tolerance — all in an app a doctor could build in a weekend. Three days of fluid retention caught before the ICU admission. Cost: twenty dollars a month. The fix has arrived. The system isn't using it. About the GuestBeverly Gage is the John Lewis Gaddis Professor of History and American Studies at Yale. She is the author of G-Man: J. Edgar Hoover and the Making of the American Century, which won the Pulitzer Prize for Biography, and This Land Is Your Land: A Road Trip Through US History. She is currently at work on a biography of Ronald Reagan.References:•       This Land Is Your Land: A Road Trip Through US History by Beverly Gage.•       G-Man: J. Edgar Hoover and the Making of the American Century by Beverly Gage — the Pulitzer-winning biography.•       Episode 2859: Stop, Don't Do That — Peter Edelman on Bobby Kennedy and the heart of America. The companion conversation.About Keen On AmericaNobody asks more awkward questions than the Anglo-American writer and filmmaker Andrew Keen. In Keen On America, Andrew brings his pointed Transatlantic wit to making sense of the United States — hosting daily interviews about the history and future of this now venerable Republic. With nearly 2,800 episodes since the show launched on TechCrunch in 2010, Keen On America is the most prolific intellectual interview show in the history of podcasting.WebsiteSubstackYouTubeApple PodcastsSpotify Chapters:(00:31) - Introduction: AI and the American healthcare sector (01:47) - ChatGPT MD: chronic disease and the trillion-dollar opportunity (04:50) - The stealth revolution: 40% of patients, 80% of doctors (06:53) - Ultra stability: the 2010-vs-2026 biopsy (09:50) - Three years of generative AI and counting (11:13) - Will the system collapse? No — it will quietly ration (13:33) - The drip-drip of preventable deaths (16:08) - GLP-1 drugs: $5 to make, $400 to buy (18:23) - Vibe coding enters the conversation (21:22) - Will AI replace clinicians? (28:08) - Trump Rx and why it won't help most people (30:41) - RFK Jr., vaccines, and the war on science (33:23) - The midterms as the political reckoning (35:29) - The three-step fix: capitation, transition, capital (39:48) - Vibe coding and the heart failure example

April 3, 2026 In this episode, Scott, Mark, and Dr. Ray Painter tackle two areas where interpretation is driving real-world coding challenges: when a prostate biopsy truly qualifies as a stereotactic template-guided saturation biopsy (55706), and whether diagnostic cystoscopy meets moderate risk under E/M guidelines. The discussion breaks down what differentiates saturation biopsy from standard transperineal approaches, including the importance of 3D templating and full-gland sampling, and why payer expectations may not align with physician interpretation. They also revisit the E/M risk table, reinforcing why cystoscopy is generally considered moderate risk—even if not explicitly stated in current guidelines. The key takeaway: as coding becomes more nuanced, balancing guideline interpretation with payer expectations is critical to staying compliant and getting paid correctly. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Drs. Petri and Woolfson discuss a simple risk score using autoantibodies, complement, and demographics to predict which SLE patients are most likely to develop proteinuria and lupus nephritis. They also highlight evidence showing that earlier kidney biopsies at lower proteinuria levels, especially in patients with low complement, can detect serious disease sooner and improve outcomes.

Send us Fan Mail Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Support the showThis episode features answers to health and cancer-related questions from Dr. Lodi's social media livestreams.Join Dr. Lodi's FREE Q&A livestreams every Sunday on Facebook, Instagram, and Tiktok (@drthomaslodi) and listen to the replays here.Submit your question for next Sunday's Q&A Livestream here:https://drlodi.com/live/Facebookhttps://www.facebook.com/DrThomasLodi/Instagramhttps://www.instagram.com/drthomaslodi/Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option.Learn to Thrive with ADHD PodcastWelcome to the Learn to Thrive with ADHD Podcast. This is the show for you if you're...Listen on: Apple Podcasts   SpotifyJoin Dr. Lodi's informative FREE Livestreams on social media...

Samina Farid built her career in oil and gas, founded her own company, and forged ahead in spaces where women are rarely seen. Through it all, she faced cancer twice and found strength that reshaped both her health and her work. - Breaking barriers as the only woman in the room - Building success in a male-dominated industry - Facing cancer two times and turning challenges into purpose Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. How did Samina Farid cope with the challenges of being the only woman in a male-dominated field? 2. How did Samina come to start her own company, and what inspired its mission? 3. What was unique about Merrick Systems, and how did it contribute to the industry? 4. Why did Samina decide to sell her company, and what was that process like? 5.What steps did Samina take after her cancer diagnosis? 6. What did Samina learn about her genetic risk for cancer? 7. How did journaling and self-care practices help Samina during her cancer journey? 8. What message does Samina want to share with other women about health and self-care? Timestamped Overview 00:00 Discovery of Remarkable Women 04:12 Pre-Internet Oil Data Challenges 08:20 Grateful for Mentorship Journey 11:27 "Turbulent Life Changes" 15:44 Cancer Journey and Support 21:23 "Facing Cancer's Uncertainty" 24:12 Genetic Mutation: Cancer Risk Alert 25:44 Pancreatic Tumor and Whipple Surgery 28:49 Prioritize Health: Just Do ItSee omnystudio.com/listener for privacy information.

In this episode, Therese Markow and Dr. John Kisiel discuss early cancer detection using liquid biopsies. Dr. Kisiel explains that liquid biopsies detect cancer signals in blood and urine, including tumor cells, fragments, proteins, and DNA. He highlights the FDA's approval of a blood test for colon cancer and the development of multi-cancer early detection tests. Dr. Kisiel notes that false positive and false negative rates vary by test. He emphasizes the potential of liquid biopsies to complement, not replace, standard screening methods and the need for further validation and clinical trials. Key Takeaways: Liquid biopsies have been used in the oncology community to test if cancer is still present, may need additional or more aggressive treatment, or if the cancer has come back. Each test will have its own false positive and false negative rate, partially based on where manufacturers set the thresholds for that positive/negative result. Peripheral blood-based tests for colon cancer do not detect polyps, and it's the finding and removing of polyps that actually offers the greatest preventive benefit, so that somebody never gets cancer in the first place.    "Another word of cautious optimism, I think that I, personally, and many other people active in the space really view these as an addition to standard of care cancer screening and not a replacement." —  Dr. John Kisiel   Connect with Dr. John Kisiel: Professional Bio: https://www.mayo.edu/research/faculty/kisiel-john-b-m-d/bio-00092659    Connect with Therese: Website:  www.criticallyspeaking.net Bluesky: @CriticallySpeaking.bsky.social Instagram: @criticallyspeakingpodcast Email: theresemarkow@criticallyspeaking.net   Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it. 

Will RFK Jr.'s efforts to promote nutrition education in medical schools stall? Doctors-in-training embrace “culinary medicine”; As Administration relaxes their regulation, PFAS compounds shown to accelerate biological aging; Is there a cure for ringing in the ears? Biopsies reveal microplastics in 90% of prostate cancers; Can you trust the results of your on-line gut microbiome test? Can sunlight tame autoimmune disease? Birdwatchers have enhanced brain regions for attention and perception. Can one have dental x-rays and a brain MRI on the same day?

Welcome to Season 2 of the Orthobullets Podcast.In this episode, we review the high-yield topic of ⁠⁠Biopsy Principles ⁠from the Pathology section.⁠Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Orthobullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Social Media:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube

Are mammograms truly protecting women — or is it time to rethink how we approach breast health? In this powerful and deeply nuanced conversation, Dr. Anna Cabeca sits down with former fellowship-trained breast surgeon turned integrative oncologist Dr. Jenn Simmons to unpack one of the most important questions in women's health today: Are mammograms safe — and are they enough? Together, they explore how conventional breast cancer screening became the standard, what the research actually says about radiation exposure and screening frequency, and why early detection is not the same as prevention. Dr. Simmons shares her personal turning point — from 17 years at the forefront of breast oncology to leaving conventional medicine and founding Real Health MD after her own health crisis. What she discovered changed everything: inflammation, toxicity, hormone disruption, and metabolic dysfunction matter far more than women are being told. This episode goes beyond mammograms. It dives into: • Radiation risks and over-screening • Alternative imaging options including thermography, ultrasound, and emerging technologies • Hormones and breast cancer — clearing the misinformation • Why anti-estrogen messaging can be harmful and incomplete • Bioidentical progesterone and protective mechanisms • Birth control pills and breast development risk • The power of metabolic health, fasting windows, detoxification, and terrain theory Most importantly, this conversation restores agency. You are not powerless when it comes to breast health. Knowledge is evolving. Screening is evolving. Hormone science is evolving. And you deserve the full picture. –––––––––––––––––– KEY TIMESTAMPS 00:00 Reimagining breast health and questioning the narrative 01:23 Introducing Dr. Jenn Simmons and her paradigm shift 09:47 From breast surgeon to integrative oncologist: her turning point 12:28 Functional medicine approach: "What caused the cancer?" 27:19 Mammography myths and reviewing the research 33:01 Radiation exposure: known carcinogen discussion 35:31 Biopsy concerns and imaging alternatives 42:07 Medical board pressures and guideline rigidity 53:04 "Anti-estrogen talk is misogynistic" 01:04:10 Birth control pills, teens, and breast cancer risk –––––––––––––––––– MEMORABLE QUOTES Dr. Jenn Simmons: "Radiation is a known carcinogen." "Any anti-estrogen talk is misogynistic." Dr. Anna Cabeca: "What caused your cancer to begin with?" "It takes more than hormones to fix our hormones." "There's always one next right step we can take to advocate for our health." –––––––––––––––––– CONNECT WITH DR. JENN SIMMONS Website: www.realhealthmd.comInstagram: @drjennsimmons YouTube: @dr.jennsimmons Book: The Smart Woman's Guide to Breast Cancer –––––––––––––––––– CONNECT WITH DR. ANNA CABECA Website: www.dranna.comInstagram: www.instagram.com/thegirlfrienddoctor YouTube: www.youtube.com/@thegirlfrienddoctor TikTok: www.tiktok.com/@drannacabeca Facebook: www.facebook.com/thegirlfrienddoctor –––––––––––––––––– If this episode spoke to you, share it with a girlfriend, your daughters, your mother — every woman deserves this conversation. You are seen. You are informed. You are empowered.

Picture this: a patient with early-stage breast cancer is sitting in front of you in the clinic. You are about to offer your expert management plan. The age-old question arises—should you really perform a sentinel lymph node biopsy, or could omission actually help this patient more? Today, we're tackling one of the hottest debates in modern breast cancer care.Should we rethink sentinel lymph node biopsy for select patients, and can skipping it actually improve quality of life without sacrificing cancer control? The stakes couldn't be higher—balancing accurate cancer staging and minimizing harm is the name of the game. Together, we're breaking down the latest evidence from the SOUND and INSEMA trials. What do these landmark studies mean for your patients, your practice, and the future of axillary management? Ready for a journal review that might just change your next consult? Hosts:- Rashmi Kumar, MD, PhDResident, University of Michigan General Surgery Residency ProgramTwitter/X: @RashmiJKumar- Melissa Pilewskie, MDAttending Breast Surgical Oncologist, Co-Director of the Weiser Family Center for Breast Cancer, Michigan Medicine Twitter/X: @MPilewskie- Stephanie Downs-Canner, MDAttending Breast Surgical Oncologist & Physician-Scientist, Memorial Sloan Kettering Cancer Center, Program Director of the Breast Surgical Oncology Fellowship Training Program Twitter/X: @SDownsCannerLearning Objectives:- Understand when and for whom it is safe and beneficial to omit sentinel lymph node biopsy (SLNB) in early-stage breast cancer patients.- Identify the risks associated with foregoing SLNB, including loss of nodal staging, and analyze how this impacts treatment selection and prognosis.- Review key findings from the SOUND and INSEMA trials and their influence on axillary management.- Discuss implications for adjuvant therapy, genomic profiling, and multidisciplinary clinical practice.- Recognize which patient populations should still receive SLNB, and the importance of individualized, multidisciplinary decision-making.References:- Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023;9(11):1557–1564. doi:10.1001/jamaoncol.2023.3759 https://pubmed.ncbi.nlm.nih.gov/37733364/- Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer – primary results of the INSEMA trial. N Eng J Med. 2024. doi:10.1056/NEJMoa2412063.https://pubmed.ncbi.nlm.nih.gov/39665649/- Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794. PMID: 31566680; PMCID: PMC6777230. https://pubmed.ncbi.nlm.nih.gov/31566680/- Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818. doi: 10.1177/17588359231201818. PMID: 37275963; PMCID: PMC10233570. https://pubmed.ncbi.nlm.nih.gov/37275963/Sponsor Disclosure: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US